Media headlines about Quidel (NASDAQ:QDEL) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Quidel earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.442522410889 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
QDEL stock opened at $49.80 on Wednesday. The company has a market capitalization of $1,693.48, a PE ratio of -207.50, a PEG ratio of 1.59 and a beta of 1.03. The company has a quick ratio of 2.06, a current ratio of 2.58 and a debt-to-equity ratio of 1.66. Quidel has a twelve month low of $21.08 and a twelve month high of $50.24.
Quidel (NASDAQ:QDEL) last announced its earnings results on Wednesday, February 21st. The company reported $0.56 EPS for the quarter, beating the consensus estimate of ($0.14) by $0.70. The business had revenue of $114.90 million for the quarter, compared to the consensus estimate of $115.06 million. Quidel had a negative return on equity of 3.02% and a negative net margin of 2.94%. The company’s revenue was up 117.6% on a year-over-year basis. During the same period last year, the business posted $0.17 EPS. equities research analysts anticipate that Quidel will post 1.22 earnings per share for the current year.
A number of equities analysts have recently commented on the company. BidaskClub upgraded Quidel from a “hold” rating to a “buy” rating in a report on Saturday, March 10th. Zacks Investment Research upgraded Quidel from a “sell” rating to a “hold” rating in a report on Friday, February 23rd. Raymond James Financial upgraded Quidel from an “outperform” rating to a “strong-buy” rating and cut their price objective for the stock from $55.00 to $47.00 in a report on Thursday, March 8th. UBS upgraded Quidel from an “outperform” rating to a “strong-buy” rating in a report on Thursday, March 8th. Finally, Canaccord Genuity restated a “buy” rating and issued a $52.00 price objective (up from $48.00) on shares of Quidel in a report on Thursday, December 21st. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $53.50.
In related news, CEO Douglas C. Bryant sold 36,000 shares of the firm’s stock in a transaction dated Friday, December 29th. The stock was sold at an average price of $44.10, for a total transaction of $1,587,600.00. Following the sale, the chief executive officer now directly owns 286,493 shares in the company, valued at approximately $12,634,341.30. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Jack W. Schuler sold 4,000 shares of the firm’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $44.60, for a total value of $178,400.00. Following the sale, the director now owns 3,365,553 shares in the company, valued at $150,103,663.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 169,880 shares of company stock worth $7,641,522. Company insiders own 22.00% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://transcriptdaily.com/2018/03/21/quidel-qdel-given-coverage-optimism-rating-of-0-20.html.
Quidel Company Profile
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.